Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings

International Clinical Psychopharmacology

Volumn 11, Issue 1, 1996, Pages 37-44

  Blier, P ^a   Bergeron, R ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

antidepressant drugs; pindolol; serotonin receptors; serotonin reuptake inhibitors; tryptophan

Indexed keywords

5 HYDROXYTRYPTOPHAN; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; PAROXETINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; OBSESSION; PRIORITY JOURNAL;

EID: 0029883579     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199603000-00005     Document Type: Article

References (43)

1. 3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis. Drugs, 42, 551-568.
2. Artigas F, Perez V and Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin uptake inhibitors. Archives of General Psychiatry, 51, 248-251.
3. Aulakh CS, Wozniak KM, Haas M, Hill JL, Zohar J and Murphy DL (1988) Food intake, neuroendocrine and temperature effects of 8-OH-DPAT in the rat. European Journal of Pharmacology, 146, 253-259.
4. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS and Price LH (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Archives of General Psychiatry. 51, 309-317.
5. Beattie DT and Connor HE (1995) The pre- and post-junctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan. European Journal of Pharmacology, 276, 271-276.
6. Bergeron R and Blier P (1994) Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. American Journal of Psychiatry, 151, 1084-1086.
7. 1A receptors. European Neuropsychopharmacology, 5, 277-278.
8. Bland RC, Newman SC and Orn H (1988) Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatrica Scandinavica, 77 (Suppl 338), 24-32.
9. Blier P and Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology, 15, 217-222.
10. Blier P and Bouchard C (1994) Modulation of serotonin release in the guinea pig brain following long-term administration of antidepressant drugs. British Journal of Pharmacology, 113, 485-495.
11. de Montigny C (1994) Lithium addition in treatment-resistant depression. International Clinical Psychopharmacology, 9 (Suppl 2), 31-35.
12. 1D receptors in guinea pig brain: effect of n-ethylmaleimide and paroxetine. Society for Neuroscience Abstracts, 21, 113.2.
13. El Mansari M, Bouchard C and Blier P (1995) Alteration of serotonin release by selective serotonin reuptake inhibitors in the guinea pig orbitofrontal cortex: relevance to the treatment of obsessive-compulsive disorder. Neuropsychopharmacology, 13, 117-127.
14. 3H]5-hydroxytryptamine in slices of human neocortex. Journal of Neurochemistry, 59, 1293-1301.
15. Goodman WK, Rasmussen SA, Foa EB and Price LH (1994) Obsessive compulsive disorder. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines (Eds RF Prien and DS Robinson), pp. 431-466. Raven Press, New York.
16. Greist J, Chouinard G, DuBoff E, Malaris A, Won Kim S, Koran L, Liebowitz M, Lydiard B, Rasmussen S, White K and Sikes C (1995) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry, 52, 289-295.
17. Insel TR (1992) Toward a neuroanatomy of obsessive-compulsive disorder. Archives of General Psychiatry, 49, 739-744.
18. Jacobsen FM (1991) Possible augmentation of antidepressant response by buspirone. Journal of Clinical Psychiatry, 52, 217-220.
19. Jenike MA, Baer L and Buttolph L (1991) Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Journal of Clinical Psychiatry, 52, 13-14.
20. Joffe RT and Schuller DR (1993) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Journal of Clinical Psychiatry, 54, 269-271.
21. Joffe RT, Singer W, Levitt AJ and MacDonald C (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refactory depression. Archives of General Psychiatry, 50, 387-393.
22. Karno M, Golding JM, Sorenson SB and Burnam MA (1988) The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry, 45, 1094-1099.
23. Katz RJ and De Veaugh-Geiss J (1990) The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Research, 31, 121-129.
24. Leonard HL, Swedo SE, Lanane MC, Rettew DC, Cheslow DL, Hamburger SD and Rapoport JL (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 48, 922-927.
25. Markowitz PJ, Stagno SJ and Calabrese JR (1990) Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry, 147, 798-800.
26. McDougle CJ, Price LH, Goodman WK, Charney DS and Heninger GR (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175-184.
27. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR and Price LH (1993) Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry, 150, 647-649.
28. Montgomery SA (1980) Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceutical Medicine, 1, 189-192.
29. Montgomery SA (1994) Pharmacological treatment of obsessive-compulsive disorder. In: Current Insights in Obsessive Compulsive Disorder (Eds E Hollander, J Zohar, D Marazziti and B Olivier), pp. 215-226. Wiley, New York.
30. Montgomery SA, Fineberg N, Montgomery D and Bullock T (1992) L-Tryptophan in obsessive compulsive disorder - a placebo controlled study. European Neuropsychopharmacology, 2, 384-385.
31. Nelson JC, Mazure CM, Bowers MB and Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry, 48, 303.
32. Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE and Murphy DL (1991) A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 11, 242-248.
33. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE and Murphy DL (1992) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 11-18.
34. 1D receptors. Society for Neuroscience Abstracts, 19, 93.4.
35. 1B knock-out mice: experiments in hippocampal, frontal cortex and midbrain raphe slices. Neuro Report, 7, 1353-359.
36. Rasmussen SA (1981) Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. American Journal of Psychiatry, 141, 1283-1285.
37. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology, in press.
38. 1D receptor antagonist GR 127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology, 34, 377-382.
39. 1A autoreceptors modulate 5-HT release in the guinea pig dorsal raphe nucleus. Neuropharmacology, 33, 393-402.
40. Stone TW, Connick JH, Burton NR and Smith DAS (1987) Quinolinic and kynurenic acids as endogenous ligands at NMDA receptors. Neurology and Neurobiology, 24, 147-152.
41. Tollefson GD, Ramprey AM, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear MK, Goodman W and Genduso LA (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51, 559-567.
42. 1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. European Journal of Pharmacology, 106, 271-282.
43. Zohar J and Insel TR (1987) Obsessive compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biological Psychiatry, 22, 667-690.